AustriaResearch and clinical trials
Omaveloxolone treatment for Friedreich ataxia may raise "bad" cholesterol
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
In Vienna, 17 adults with Friedreich ataxia who started omaveloxolone treatment were followed for one year. Shortly after treatment began, blood cholesterol rose. The increase came almost entirely from LDL, known as "bad" cholesterol. LDL levels stayed high throughout the year.
What does it mean for patients and families?
Regular monitoring of blood fats may be useful in people taking this drug. Do not stop the drug on your own; discuss the results with your doctor.
Source
Scientific paper: Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis. CNS Drugs, 2026. DOI: 10.1007/s40263-026-01312-w · PubMed 42371397
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Friedreich ataxia
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.